Ocumension Therapeutics announce that Mr. Zhenyu ZHANG has been appointed as an independent non-executive director, the chairman of the remuneration committee and a member of the nomination committee and audit committee of the Company with effect from April 8, 2022. Mr. Zhang, aged 46, has more than 20 years of experience in legal and corporate compliance practice. He currently serves as the vice president responsible for legal, compliance and governmental affairs of Greater China region for The a2 Milk Company Limited.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.03 HKD | +1.17% | +3.25% | -9.73% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 528M | |
+25.73% | 672B | |
+25.87% | 570B | |
-5.07% | 360B | |
+16.82% | 321B | |
+8.44% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.77% | 149B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee